{"nctId":"NCT00761150","briefTitle":"Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","startDateStruct":{"date":"2008-09"},"conditions":["Chronic Low Back Pain"],"count":308,"armGroups":[{"label":"Open-label ABT-712","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-712"]},{"label":"Double-blind ABT-712","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-712"]},{"label":"Double-blind Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ABT-712","otherNames":["Hydrocodone and acetaminophen extended-release","Hydrocodone bitartrate and acetaminophen extended-release"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male and female subjects who voluntarily sign the informed consent\n* Diagnosis of CLBP of 6 months duration\n\nExclusion Criteria:\n\n* Incapacitated or bedridden subjects\n* Subjects with history of surgical or invasive intervention","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)","description":"The change from the DB randomization baseline (DB baseline: the last assessment before first dose in the DB period) to the final assessment in pain intensity, assessed using the CLBP Intensity VAS (0 mm = No Pain and 100 mm = Worst Pain Imaginable). Least squares means and standard errors from 2-way ANCOVA model without interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.41"},{"groupId":"OG001","value":"18.0","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Change From Double-blind (DB) Baseline to Final Assessment in Chronic Pain Sleep Inventory (CPSI)","description":"The change from the DB randomization baseline (DB baseline: the last assessment before first dose in the DB period) to the final assessment of the impact of pain on the participant's sleep. The CPSI utilizes a 100 mm VAS scale for questions of how often the participant had trouble falling asleep because of pain, needed sleeping medication, was awakened by pain during the night, and was awakened by pain in the morning (0 mm = Never and 100 mm = Always); and for rating the overall quality of sleep (0 mm = Very Poor and 100 mm = Excellent). Least squares means and standard errors from 2-way ANCOVA model without interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"2.43"},{"groupId":"OG001","value":"13.1","spread":"2.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"2.04"},{"groupId":"OG001","value":"8.4","spread":"2.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.52"},{"groupId":"OG001","value":"15.1","spread":"2.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.62"},{"groupId":"OG001","value":"13.0","spread":"2.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.59"},{"groupId":"OG001","value":"-13.9","spread":"2.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":308},"commonTop":["CONSTIPATION","NAUSEA","HEADACHE","SOMNOLENCE","VOMITING"]}}}